Overview of pharmacological approaches to therapy for Tourette syndrome.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002648:Child; D003000:Clonidine / Q000627:therapeutic use; D003342:Corpus Striatum / Q000503:physiopathology; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008297:Male; D010640:Phenothiazines; D010868:Pimozide / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000502:physiology; D005879:Tourette Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D014150:Antipsychotic Agents; D010640:Phenothiazines; D011954:Receptors, Dopamine; D010868:Pimozide; D006897:Hydroxyindoleacetic Acid; D005680:gamma-Aminobutyric Acid; D006916:5-Hydroxytryptophan; D006220:Haloperidol; D003000:Clonidine